Neurocrine Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0K6R.L | NMRA | NEU.AX | ACAD | ATAI | PRAX | |
|---|---|---|---|---|---|---|
| Market cap | — | 75.40M | 2.51B | 3.49B | — | 7.22B |
| P/E (TTM) | 193.6 | — | 132.1 | 9.1 | — | — |
| Forward P/E | — | -0.6 | 33.2 | 22.0 | — | -27.2 |
| Price/book | 3.9 | 1.7 | 7.5 | 2.7 | — | 5.4 |
| Dividend yield | — | — | 1.52% | — | — | — |
| 1-year change | +51.35% | −81.99% | −5.40% | −7.09% | — | +44.08% |
| Today | +3.27% | −3.53% | +0.56% | +0.40% | 0.00% | +0.76% |
The closest companies by business. Prices may be delayed up to 20 min.
Latest news
All 0K6R.L news ›Neurocrine Biosciences starts 135‑patient Alzheimer's cognition trial
The placebo-controlled study tests two doses of NBI-'567 over 12 weeks, with primary completion estimated for May 2028. A trial targeting 135 patients with Alzheimer's cognitive impairment has begun, as Neurocrine Biosciences, Inc.…
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
TradingView Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment
Neurocrine Biosciences has launched a Phase 2 clinical trial for NBI-1117567 (NBI-'567), an oral drug targeting muscarinic receptors to improve cognition in adults with mild to moderate Alzheimer's disease. The study will test the drug's…
Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target
Needham reiterated their Buy rating on Neurocrine Biosciences's stock with a price target of $204.00. The price target implies an upside of 49.0% from the Oct 15 close of $136.95. Strong Portfolio of Approved Treatments: Neurocrine…
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Oct 16, 2026, 08:30 ET Routine clinical records captured substantial challenges beyond medical complications, extending to school, work, and daily functioning. These impacts evolved over time from challenges managing treatment and…
Neurocrine Biosciences: JPMorgan reports 5.2% stake
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) Stock Titan - [SCHEDULE 13G/A] NEUROCRINE BIOSCIENCES INC Amended Passive Investment Disclosure Neurocrine Biosciences: JPMorgan reports 5.2% stake Neurocrine Biosciences,…
Neurocrine Biosciences, Inc. $NBIX Stock: Ninety One UK Ltd Increases Stake
Ninety One UK Ltd boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 160,372.7% during the 3rd quarter, Holdings Channel reports. The firm owned 434,881 shares of the company’s stock after buying an additional…
Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
Two months after the release of an open letter on potential safety issues tied to a rare disease drug sold by Neurocrine Biosciences, patient advocates and some experts are expressing growing alarm over the perceived risks of the therapy.…
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Axsome offers faster growth, while Neurocrine brings profitability and a more established business, but which stock offers the better investment opportunity? Axsome Therapeutics, Inc. (NASDAQ:AXSM) and Neurocrine Biosciences, Inc.…
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Oct 12, 2026, 16:01 ET Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
stocktitan.net3
-
themarketsdaily.com2
-
contractpharma.com1
-
defenseworld.net1
-
insidermonkey.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.